Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT
一项针对异基因造血干细胞移植后高危急性髓系白血病患者的II期临床研究,评估了西达米德和阿扎胞苷双重表观遗传靶向治疗的疗效。
期刊:Clinical Epigenetics
影响因子:4.4
doi:10.1186/s13148-025-01987-w
Wu, Ya-Xue; Wan, Chao-Ling; Tan, Kai-Wen; Zhang, Yang; Zhang, Yan-Ming; Zhang, Hao; Wu, De-Pei; Chen, Su-Ning; Wang, Ying; Ma, Xiao; Dai, Hai-Ping; Qian, Chong-Sheng; Jiang, Shan-Shan; Bao, Hai-Yan; Hu, Xiao-Hui; Li, Zheng; Xue, Sheng-Li